专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

TW200500109A 收容藥劑之無針注射器 NEEDLE-LESS SYRINGECONTAINED WITH MEDICAMENT 审中-公开
简体标题：收容药剂之无针注射器 NEEDLE-LESS SYRINGECONTAINED WITH MEDICAMENT
公开(公告)号：TW200500109A
公开(公告)日：2005-01-01
申请号：TW093112714
申请日：2004-05-06
申请人：森下龍一 MORISHITA, RYUICHI , 安琪士摩奇股份有限公司 ANGES MG, INC. , 島津製作所股份有限公司 SHIMADZU CORPORATION
发明人：森下龍一 MORISHITA, RYUICHI , 富田奈留也 TOMITA, NARUYA , 座康夫 KUNUGIZA, YASUO , 谷山義明 TANIYAMA, YOSHIAKI , 小池弘美 KOIKE, HIROMI , 宇田川晴英 UDAGAWA, HARUHIDE , 木村辰男 KIMURA, TATSUO
IPC分类号： A61M
CPC分类号： A61M5/30 , A61K38/1833 , A61K48/00
摘要：本發明係提供一種收容含有基因及／或其類似體之醫藥製劑之無針注射器。該無針注射器，係為一種包括具有一個或複數個噴嘴孔25並收容有藥劑之藥劑室22、以及具備將該藥液L朝噴嘴孔25的方向推壓以從上述噴嘴孔25噴射藥液L用之推壓機構32的注射器本體12之無針注射器；其中之藥液L係含有基因及／或其類似體之醫藥製劑。藥液L的例子，舉例來說，例如可以是含有HGF基因之醫藥製劑、以及NF–κB引誘體寡核酸之醫藥製劑等。
简体摘要：本发明系提供一种收容含有基因及／或其类似体之医药制剂之无针注射器。该无针注射器，系为一种包括具有一个或复数个喷嘴孔25并收容有药剂之药剂室22、以及具备将该药液L朝喷嘴孔25的方向推压以从上述喷嘴孔25喷射药液L用之推压机构32的注射器本体12之无针注射器；其中之药液L系含有基因及／或其类似体之医药制剂。药液L的例子，举例来说，例如可以是含有HGF基因之医药制剂、以及NF–κB引诱体寡核酸之医药制剂等。

2. 发明专利

AT530197T 未知
公开(公告)号：AT530197T
公开(公告)日：2011-11-15
申请号：AT07021738
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K45/00 , A61K31/5585 , A61K31/711 , A61K38/16 , A61K38/17 , A61K38/18 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

3. 发明公开

EP1889633A1 Medicinal compositions for angiogenic therapy 有权
标题翻译： Medizinische Zusammensetzungen zur Angiogenese-Therapie
公开(公告)号：EP1889633A1
公开(公告)日：2008-02-20
申请号：EP07021738.5
申请日：2001-06-27
申请人： AnGes MG, Inc. , Morishita, Ryuichi
发明人： The designation of the inventor has not yet been filed
IPC分类号： A61K45/00 , A61K48/00 , A61K31/711 , A61K38/18 , A61K31/5585 , A61P9/00 , A61P9/10 , A61K38/16
CPC分类号： A61K38/52 , A61K31/5585 , A61K31/711 , A61K38/1709 , A61K38/1833 , A61K38/1858 , A61K48/00 , A61K2300/00
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.
摘要翻译：本发明提供：（1）血管生成治疗用药物组合物，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分，以及生成它们的物质; 和编码血管生成因子的基因; （2）用于增强编码血管生成因子的基因的血管生成作用的药剂，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分; （3）含有前列环素合酶基因作为活性成分的血管生成剂; （4）含有ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; （4）含有ets-1基因作为增强编码血管生成因子的另一基因的血管生成作用的活性成分的药剂; 和（5）含有ets-1基因作为活性成分的血管发生剂。

4. 发明公开

EP1300158A1 MEDICINAL COMPOSITIONS FOR ANGIOGENIC THERAPY 有权
标题翻译：药剂师ZUBEREITUNGEN ZUR ANGIOGENESE-THERAPIE
公开(公告)号：EP1300158A1
公开(公告)日：2003-04-09
申请号：EP01943840.7
申请日：2001-06-27
申请人： MedGene Bioscience, Inc. , Morishita, Ryuichi
发明人： MORISHITA, Ryuichi , KOIKE, Hiromi , TANABE, Tadashi , AOKI, Motokuni
IPC分类号： A61K45/00 , A61K48/00 , A61K31/711 , A61K38/18 , A61K31/5585 , A61P9/00 , A61P9/10
CPC分类号： A61K38/52 , A61K31/5585 , A61K31/711 , A61K38/1709 , A61K38/1833 , A61K38/1858 , A61K48/00 , A61K2300/00
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.
摘要翻译：本发明提供：（1）血管生成治疗用药物组合物，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分，以及生成它们的物质; 和编码血管生成因子的基因; （2）用于增强编码血管生成因子的基因的血管生成作用的药剂，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分; （3）含有前列环素合酶基因作为活性成分的血管生成剂; （4）含有ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; （4）含有ets-1基因作为增强编码血管生成因子的另一基因的血管生成作用的活性成分的药剂; 和（5）含有ets-1基因作为活性成分的血管发生剂。

5. 发明专利

CA2413768A1 PHARMACEUTICAL COMPOSITIONS FOR ANGIOGENIC THERAPY 未知
公开(公告)号：CA2413768A1
公开(公告)日：2002-01-03
申请号：CA2413768
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： AOKI MOTOKUNI , MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI
IPC分类号： A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10 , A61K45/00 , A61K38/18
摘要： Medicinal compositions for angiogenic therapy which contain as the active ingredients at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same, and a gene encoding an angiogenesis factor; agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain as the active ingredient at least one memb er selected from among substances having a vasodilating effect and/or a platele t aggregation inhibitory effect and substances producing the same; an angiogen ic agent which contains prostacyclin synthase gene as the active ingredient; medicinal compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; an agent for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain ets-1 gene as the active ingredient; and a n angiogenic agent which contains ets-1 gene as the active ingredient.

6. 发明专利

DE60134021D1 未知
公开(公告)号：DE60134021D1
公开(公告)日：2008-06-26
申请号：DE60134021
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K45/00 , A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/43 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10 , C12N15/19 , C12N15/52
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

7. 发明专利

AT395071T 未知
公开(公告)号：AT395071T
公开(公告)日：2008-05-15
申请号：AT01943840
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K38/18 , A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/43 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10 , C12N15/19 , C12N15/52
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

8. 发明专利

AU2001266338B8 Pharmaceutical compositions for angiogenic therapy 未知
公开(公告)号：AU2001266338B8
公开(公告)日：2006-12-14
申请号：AU2001266338
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： AOKI MOTOKUNI , KOIKE HIROMI , TANABE TADASHI , MORISHITA RYUICHI
IPC分类号： A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

9. 发明专利

CA2348906A1 GENE THERAPY FOR CEREBROVASCULAR DISORDERS 未知
公开(公告)号：CA2348906A1
公开(公告)日：2001-03-29
申请号：CA2348906
申请日：2000-09-18
申请人： MEDGENE BIOSCIENCE INC , MORISHITA RYUICHI
发明人： OGIHARA TOSHIO , MORISHITA RYUICHI
IPC分类号： A61K35/76 , A61K38/18 , A61K38/19 , A61K48/00 , A61P9/00 , A61P9/10 , A61P25/00 , A61P25/28 , A61P43/00
摘要： Cerebrovascular disorders (cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, cerebral attack, cerebral hemorrhage , Willis' circle occlusion, cerebrovascular dementia, Alzheimer's dementia, etc.) can be efficaciously treated or prevented by transferring an HGF (hepatocyte growth factor) gene and/or a VEGF (vascular endothelial growth factor) gene into the subarachnoidal space of humans.

10. 发明专利

AU2001266338B2 Medicinal compositions for angiogenic therapy 未知
公开(公告)号：AU2001266338B2
公开(公告)日：2006-11-09
申请号：AU2001266338
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： AOKI MOTOKUNI , KOIKE HIROMI , TANABE TADASHI , MORISHITA RYUICHI
IPC分类号： A61K45/00 , A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式